Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Esserman

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Research Square|July 17, 2025
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerJustin Balko, Xiaopeng Sun, Ann Hanna, et al.
Journal of the American Medical Informatics Association : JAMIA|August 19, 2024
Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancerAnna Northrop, Anika Christofferson, Saumya Umashankar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mappingJulia D Wulfkuhle, Daniela Berg, Claudia Wolff, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 25, 2015
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working groupElena Provenzano, Veerle Bossuyt, Giuseppe Viale, et al.
NPJ Breast Cancer|March 26, 2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence riskMark Jesus M Magbanua, Wen Li, Denise M Wolf, et al.
Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.
Journal of the National Cancer Institute|June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRODavid M Euhus, Kristin C Smith, Linda Robinson, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2020
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)E Shelley Hwang, Terry Hyslop, Laura H Hendrix, et al.
BMC Cancer|November 26, 2008
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signatureAndrew Tutt, Alice Wang, Charles Rowland, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Research Square|July 17, 2025
Peripheral blood gene expression signatures of systemic immunity predict tumor microenvironment biology and therapeutic response in breast cancerJustin Balko, Xiaopeng Sun, Ann Hanna, et al.
Journal of the American Medical Informatics Association : JAMIA|August 19, 2024
Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancerAnna Northrop, Anika Christofferson, Saumya Umashankar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mappingJulia D Wulfkuhle, Daniela Berg, Claudia Wolff, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 25, 2015
Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working groupElena Provenzano, Veerle Bossuyt, Giuseppe Viale, et al.
NPJ Breast Cancer|March 26, 2021
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence riskMark Jesus M Magbanua, Wen Li, Denise M Wolf, et al.
Cancer|February 14, 2014
Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2Sarah A Jackson, Andrew A Davis, Jun Li, et al.
Journal of the National Cancer Institute|June 6, 2002
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRODavid M Euhus, Kristin C Smith, Linda Robinson, et al.
NPJ Breast Cancer|September 27, 2017
DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trialDenise M Wolf, Christina Yau, Ashish Sanil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2020
Phase II Single-Arm Study of Preoperative Letrozole for Estrogen Receptor-Positive Postmenopausal Ductal Carcinoma In Situ: CALGB 40903 (Alliance)E Shelley Hwang, Terry Hyslop, Laura H Hendrix, et al.
BMC Cancer|November 26, 2008
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signatureAndrew Tutt, Alice Wang, Charles Rowland, et al.
Pageof 15